ClinicalTrials.gg
Active, not recruitingNCT07039942OPTIMAL-AUpdated Aug 3, 2026

French Prospective Multicentric Study in Real World

An observational study in Diabetes, Diabetes Mellitus and Type 1 Diabetes, sponsored by Insulet Corporation. Active, not recruiting at 24 sites in France. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Insulet Corporation · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
304
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.

Started
2025
the only one that year
Observational
3 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is the only one that started in 2025, is one of 3 observational ones, and was the 11th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, or all of them as a file.
02

Study summary

The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.

Read the detailed description

Twelve-month, real-world, non-interventional, prospective follow-up of adult and pediatric patients aged more than 2 years old, prescribed one of the Dexcom (Dexcom G6 or G7) configurations commercially available of the Omnipod 5 Automated Insulin Delivery System in France.

OPTIMAL-A study (Omnipod 5 - A French Prospective Multicentric Study in Real World), aims to provide the requisite real-world data on the glycemic control, quality of life, safety, and device usage profiles of users of the Omnipod 5 System during the 12 months after starting using Omnipod 5 in automated mode.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus
  • Type 1 Diabetes

Browse trials for

Keywords

  • Type 1 Diabetes
  • Omnipod
  • Automated Insulin Delivery
  • Registry
04

In context

Diabetes Mellitus, Type 1 Reclassified

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 304 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population contains patients (age ≥ 2 years) with T1DM initiating a commercially available configuration of the Omnipod 5 System using a Dexcom sensor (Dexcom G6 or Dexcom G7) in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with T1D aged ≥ 2 years.
  • Patient prescribed a commercially available configuration of the Omnipod 5 System using a Dexcom sensor (Dexcom G6 or Dexcom G7).
  • Patient has never used the Omnipod 5 System prior to inclusion.
  • Patient has not objected to the use of their personal data for this study.
  • Patient or legal guardian has an email address and mobile phone number.
  • Patient (and legal guardians if the patient is a minor) is able to understand study information and Non-Opposition form.
  • Patient (and legal guardians if the patient is a minor) is able to understand and complete questionnaires in French.
  • Patient is covered by the local social security system.

Exclusion criteria

Exclusion Criteria:

  • Patient is currently pregnant
  • Patient presents an allergy to the materials of the Omnipod 5 System (patch, cannula, CGM).
  • Patient is unable to be followed by the same investigation site for the duration of the study or is unwilling or unable to maintain contact with the healthcare professional.
  • Patient is already participating in a clinical trial or in another study precluding their participation in other studies.
  • Patient or legal guardian (for minors) is not able to understand and complete electronic questionnaires.
  • Adult under guardianship, curatorship or tutorship.
  • Adult otherwise deprived of liberty.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
304 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Omnipod 5 User

    Participation of each patient begins at inclusion and continues until the end-of-study visit, 12 months (± 1 month) following first initiation of automated mode of the Omnipod 5 System

    Device: Omnipod 5

Interventions

  • DeviceOmnipod 5

    The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin. The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems.

07

What researchers measure

Primary outcomes

  1. Change in the percentage of time in the 70 - 180 mg/dL range (TIR)

    Assess the effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: 12 months following first initiation of automated mode

Secondary outcomes

  1. Percentage of time in the 70 - 180 mg/dL range (TIR)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  2. Percentage of time in the 70 - 140 mg/dL range (TIR Tight)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  3. Percentage of time below 54 mg/dL (TBR Very Low)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  4. Percentage of time below 70 mg/dL (TBR Low)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  5. Percentage of time above 180 mg/dL (TAR High)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  6. Percentage of time above 250 mg/dL (TAR Very High)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  7. Glucose Management Indicator (GMI)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  8. Glycemic Risk Index (GRI)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  9. Coefficient of variation (CV)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  10. Mean glucose

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  11. Laboratory HbA1c levels (if available)

    Assess the sustained effectiveness of the Omnipod 5 system in terms of glycemic control

    Time frame: Up to 12-months following first initiation of automated mode

  12. Percentage of patients with ≥ 70% TIR

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  13. Percentage of patients with < 4% TBR Low

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  14. Percentage of patients with < 1% TBR Very Low

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  15. Percentage of patients with GMI ≤ 7%

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  16. Percentage of patients with CV ≤ 36%

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  17. Percentage of patients achieving combinations of previous CGM-based consensus targets

    Assess the achievement of CGM-based consensus targets

    Time frame: Up to 12-months following first initiation of automated mode

  18. EuroQoL 5-dimension 5-level questionnaire

    Assess patients' general QoL

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  19. Patients aged ≥ 18 years: Diabetes Quality of Life - Brief Clinical Inventory

    Assess patients' diabetes-specific QoL

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  20. Patients aged 10-17 years: Diabetes Quality of Life for Youth scale - Short Form (DQOLY-SF)

    Assess patients' diabetes-specific QoL

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  21. Insulin Delivery System Rating Questionnaire (IDSRQ) interference sub-score

    Assess the interference of the Omnipod 5 System with patients' daily lives

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  22. Patients aged ≥ 18 years: Diabetes Treatment Satisfaction Questionnaire, status version (DTSQs)

    Assess patients' satisfaction with the Omnipod 5 System

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  23. Patients aged 13-17 years: Diabetes Treatment Satisfaction Questionnaire, status version - Teens (DTSQs - Teen)

    Assess patients' satisfaction with the Omnipod 5 System

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  24. Patients aged 2-12 years: Diabetes Treatment Satisfaction Questionnaire, status version - Parent (DTSQs - Parent)

    Assess patients' satisfaction with the Omnipod 5 System

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  25. Pediatric quality of life questionnaire (animated emoji scale - ad hoc)

    Assess pediatric patients' quality of life with the Omnipod 5 System

    Time frame: At inclusion and 6 and 12 months following first initiation of automated mode

  26. Percentage of time using the System in automated mode

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  27. Percentage of time using the System in manual mode

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  28. Percentage of time using "Activity" feature

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  29. Total daily dose of insulin

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  30. Number of boluses per day

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  31. Targets used by patients

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  32. Bolus/Basal distribution

    Describe System use

    Time frame: 12 months following first initiation of automated mode

  33. Incidence of severe hypoglycemia

    Assess the incidence and type of acute metabolic complications

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

  34. Incidence of diabetic ketoacidosis

    Assess the incidence and type of acute metabolic complications

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

  35. Unscheduled hospitalizations for diabetes or diabetes complications.

    Assess the incidence and type of acute metabolic complications

    Time frame: 6 months prior to switching to Omnipod 5 and over the 12 months following first initiation of automated mode

  36. Percentage of patients still using the Omnipod 5 System at the end of study follow-up.

    Assess the rate at which patients stop using the Omnipod 5 system

    Time frame: 12 months following first initiation of automated mode

  37. Reasons for having stopped using the Omnipod 5 System

    Assess the rate at which patients stop using the Omnipod 5 system

    Time frame: 12 months following first initiation of automated mode

08

Study locations

24 sites
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 24 months is close to that.

Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07039942
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jul 23, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Jean-Pierre RIVELINE, MD, PhD
principal investigator · Centre Universitaire du Diabète et ses complications Hôpital Lariboisière

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion